Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.38 |
| ▸ | SCN1A | P35498 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255338 | 0.89 | BRD4 (0.43) | PIK3C3HSD11B1SCN9A | |
| SCHEMBL3253302 | 0.85 | HSD11B1 (0.42) | CYP2C9HSD11B1PPARGSCN8ASCN1A | |
| SCHEMBL3258378 | 0.83 | HSD11B1 (0.41) | HSD11B1SCN8ASCN1ASCN5ASCN9A | |
| SCHEMBL3254082 | 0.80 | HSD11B1 (0.46) | PIK3C3HSD11B1SCN8ASCN1ASCN5A | |
| SCHEMBL6693215 | 0.79 | NMT1 (0.55) | NMT1CYP3A4CYP2C9CYP2C19PIK3C3 | |
| SCHEMBL3255842 | 0.78 | NMT1 (0.43) | NMT1CYP3A4CYP2C9CYP2C19PIK3C3 | |
| SCHEMBL3252428 | 0.78 | HSD11B1 (0.38) | HSD11B1PFKFB4SCN8ASCN1ASCN5A | |
| SCHEMBL3254728 | 0.78 | MEP1B (0.46) | HSD11B1 | |
| SCHEMBL3622234 | 0.78 | KMT2A (0.45) | NMT1CYP3A4CYP2C9CYP2C19HSD11B1 | |
| SCHEMBL3258413 | 0.77 | HSD11B1 (0.47) | HSD11B1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | claimed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | claimed |
| WO-2004112782-A1 | NEW USE V | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461325-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003043999-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7094792-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-08-22 | — | — | US | disclosed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | disclosed |
| EP-1461325-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003043999-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | NMT1 671/4885CYP3A4 139/4885CYP2C9 196/4885 |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | NMT1 666/4885CYP3A4 160/4885CYP2C9 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.